Ludwig Institute for Cancer Research Limited

Etienne DePlaen

Thierry R Boon-Falleur

Pierre Van Der Bruggen

Bernard Lethe

Pierre G Coulie

Jean-Christophe Renauld

Aline Van Pel

Vincent Brichard

Christophe Lurquin

Francis Brasseur

Thomas Wolfel

Charles DeSmet

Benoit Van Den Eynde

Beatrice Gaugler

Marie Marchand

Patrick Weynants

Francis Basseur

P Weynants

M Marchand

The invention involves the identification of peptides which complex with HLA-Cw*16 molecules, and which may then provoke lysis of the cells to which they bind, by cytolytic T cells. Diagnostic and therapeutic uses are described.

Isolated molecules which complex with HLA-Cw*16 molecules, and uses thereof

Isolated peptides which comply with HLA-CW16 molecules and uses

This invention involves the identification of peptides which complex with HLA-Cw*16 molecules, and which may then provoke lysis of the cells to which they bind, by cytolytic T cells. Diagnostic and therapeutic uses are described.

Isolated peptides which complex with HLA-Cw16 and uses thereof

The invention involves the identification of peptides which complex with HLA-Cw.sup.* 16 molecules, and which may then provoke lysis of the cells to which they bind, by cytolytic T cells. Diagnostic and therapeutic uses are described.

Isolated peptides which complex with HLA-Cw*16 molecules, and uses

The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.

Isolated tyrosinase derived peptides and uses thereof

A method for determining lung adenocarcinomas is described. The method involves assaying for expression of a gene coding for at least one of tumor rejection antigen precursors MAGE-1, 2 and 3, or their expression product.

Method for determining lung adenocarcinomas by assaying for one or more

Isolated, tyrosinase derived peptides and uses thereof

A method for determining head and neck squamous cell carcinomas, bladder tumors and prostate carcinomas is described. The method involves assaying for expression of the gene coding for tumor rejection antigen precursor MAGE-3, or its expression product. Various assays, and kits useful for these assays, are described.

Method for determining head and neck squamous cell carcinomas, prostate

Growing community of inventors

Brussels, Belgium

Etienne DePlaen